Amplyx Pharmaceuticals procures $53m

San Diego-based Amplyx Pharmaceuticals, a developer of therapies for debilitating and life-threatening diseases in patients with compromised immune systems, has raised $53 million as part of a Series C extension, which brought the round to over $90 million.

DealsHealthcareBriefs